ANNEXON INC. - COMMON STOCK

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

08 4 2025 15:05:00 提供 Nasdaq GlobeNewswire

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

03 4 2025 17:18:29 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

17 3 2025 15:05:37 提供 Nasdaq GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

03 3 2025 07:00:01 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

26 2 2025 15:05:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 2 2025 07:00:00 提供 Nasdaq GlobeNewswire

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

13 2 2025 07:30:00 提供 Nasdaq GlobeNewswire

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

13 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

10 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 1 2025 07:00:01 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 12 2024 15:05:00 提供 Nasdaq GlobeNewswire

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

16 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

05 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

15 11 2024 15:59:57 提供 Nasdaq GlobeNewswire

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

14 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

13 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

21 10 2024 19:00:41 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

15 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 9 2024 07:00:00 提供 Nasdaq GlobeNewswire